pathway is another important cell-proliferation pathway downstream of EGFR that is frequently activated in cancer. Although mutations in Ras oncogenes do not seem to coexist with EGFR mutations ...

The FDA has approved a novel combination therapy using Lumakras® (sotorasib) and Vectibix® (panitumumab) for adults with KRAS ...

The EGFR pathway has an important role in modulating angiogenesis, metastasis, cell survival and proliferation (Figure 1); therefore, inhibition of this pathway is being explored for therapeutic ...

Analyst Judah Frommer from Morgan Stanley maintained a Hold rating on ProKidney (PROK – Research Report) and keeping the price target at ...

The FDA also approved Qiagen's Therascreen KRAS RGQ PCR kit as a companion diagnostic to identify KRAS G12C-mutant patients.

As many as 15% of NSCLC patients in Europe have EGFR mutations and, as a result, are particularly sensitive to treatment with an EGFR-tyrosine kinase inhibitor that blocks the cell-signalling pathways ...

Johnson & Johnson said a combination of its lung cancer drugs Rybrevant and Lazcluze kept people alive for at least a year ...

A novel topical gel, HT-001, has shown potential as a treatment for cutaneous side effects from epidermal growth factor ...

Amivantamab targets EGFR and MET pathways and is approved in several countries for specific EGFR-driven NSCLC mutations. Subcutaneous amivantamab joins a growing list of drugs receiving complete ...